Cancer theranostics has witnessed the new era translational medicine leading
to the development of new treatment possibilities for cancer patients. The approach of
‘one-size-fits-all’ has changed from traditional methods of surgery, chemo- and
radiotherapy to that of personalised cancer medicine, molecular targeted therapy,
cancer immunotherapy, nanomedicine, alternative medicine and integrative therapy.
The clinical trials for cancer drugs have complicated, requiring better regulatory and
health policies, and collaborative efforts from the stakeholders involved in cancer drug
discovery and development. A lot has been achieved, mainly in terms of knowledge
and biological data, and the same is needed to be integrated and implemented into the
development of successful cancer theranostics. The tumour heterogeneity still poses a
challenge for scientists, but the last decade has paved a concrete pathway for the future
in precise and personalised cancer therapy.
Keywords: Alternative Medicine, Cancer Theranostics, Clinical Trials,
Immunotherapy, Integrative Therapy, Molecular Targeted Therapy,
Nanomedicine, Personalised Medicine.